Diabetes mellitus is a term that describes a metabolic syndrome of multiple etiology characterized by chronic hyperglycemia with disturbances of carbohydrates, fats and proteins metabolisms resulting from defects in insulin secretion, insulin action or both. The aim of the study was to evaluate the antidiabetic potential of lauric acid in high fat diet/streptozotocin-induced type 2 diabetic male wistar rats. Type 2 diabetes was induced by a high-fat diet (HFD) along with a low dose of streptozotocin (STZ) (30 mg/kg). Thirty Five Male Wistar rats were used in the study of which twenty five of them were diabetic. They were divided into seven groups comprising five animals each. Animals in Group 1 (Normal control) received 1 ml/kg Distilled water and Group 2 (Diabetic control) received 0.5 ml of tween 80 while those in Groups 3 (Normoglycemic) received 125 mg/kg Lauric acid, group 4, 5, 6 and 7 were administered 125, 250, 500 and 100 mg/kg body weight of lauric acid and metformin respectively orally once daily for a period of three weeks. The results showed that lauric acid at all doses significantly (P < 0.05) decreased the fasting blood glucose level after three weeks of treatment. The serum levels of TC, TG and LDL-c in diabetic treated rats were significantly (P < 0.05) reduced as compared to the diabetic control (untreated) group. While the result on high-density lipoprotein cholesterol showed a significant increase (P< 0.05) as compared to the diabetic control (untreated) group. The atherogenic risk predictor indices (CRR, AC and AIP) were significantly (P < 0.05) decreased when compared with diabetic control (untreated) group. Serum malondialdehyde (MDA) levels were significantly (P < 0.05) reduced (1.32±0.04, 1.40±0.04 and 1.42 ± 0.06 nmol/l) respectively when compared with the diabetic control (untreated) group with a value of (2.25±0.10 nmol/l), while there was up-regulated activities of serum endogenous antioxidant enzymes: SOD (1.97±0.08, 2.02±0.16, 1.98±0.12 IU/L), CAT (44.5±0.64, 43.2±0.85, 43.7±0.85 IU/L) as compared with diabetic control (untreated) (1.35±0.02 and 34.0±0.91 IU/L) respectively. Subsequent histomorphological evaluation also showed necrosis and vacuolization of islet β-cells to be reasonably reduced in the diabetic treated rats. In conclusion, the data from this study suggest that lauric acid is a potential candidate for the development of an effective drug for the management of T2D.